Shire PLC (SHP) Given Buy Rating at Shore Capital
Shire PLC (LON:SHP)‘s stock had its “buy” rating reissued by equities research analysts at Shore Capital in a research report issued to clients and investors on Monday.
Several other analysts have also weighed in on the stock. Berenberg Bank lifted their target price on shares of Shire PLC from GBX 5,900 ($77.60) to GBX 6,000 ($78.92) and gave the company a “buy” rating in a research report on Monday, November 6th. Kepler Capital Markets reissued a “buy” rating and set a GBX 4,600 ($60.50) price target on shares of Shire PLC in a report on Wednesday, November 1st. Deutsche Bank AG cut their price target on shares of Shire PLC from GBX 5,700 ($74.97) to GBX 5,500 ($72.34) and set a “buy” rating for the company in a report on Wednesday, November 1st. HSBC Holdings plc cut their price target on shares of Shire PLC from GBX 4,480 ($58.92) to GBX 4,050 ($53.27) and set a “hold” rating for the company in a report on Tuesday, October 31st. Finally, Credit Suisse Group reissued an “outperform” rating and set a GBX 4,500 ($59.19) price target on shares of Shire PLC in a report on Monday, October 30th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of GBX 5,358.82 ($70.48).
Shares of Shire PLC (LON SHP) opened at GBX 3,557.50 ($46.79) on Monday. Shire PLC has a 12-month low of GBX 3,435.50 ($45.19) and a 12-month high of GBX 5,107 ($67.17).
WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/13/shire-plc-shp-given-buy-rating-at-shore-capital.html.
In related news, insider Anne Minto bought 190 shares of the company’s stock in a transaction on Friday, September 29th. The stock was bought at an average cost of GBX 3,785 ($49.78) per share, with a total value of £7,191.50 ($9,458.77). Also, insider Flemming Ornskov bought 8,400 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was bought at an average cost of GBX 3,665 ($48.20) per share, with a total value of £307,860 ($404,919.11).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.